| Project Detail |
The global-scale pandemic crisis of COVID-19 requires precise and immediate technological solutions for virological and serological
diagnosis tests. These tests must be accurate, rapid, intelligent, and cost-efficient to prevent future rebounds of infections and help
control the pandemic. In this context, the Microelectromechanical Systems (MEMS) industry, especially piezoelectric resonators of all
shapes and sizes, is a promising strategy to revolutionize the biological detection market. Ultrahigh sensitive nanomechanical
resonators showed the potential of this technology for mass loading. Unfortunately, applying MEMS to the biomedical sector requires
challenging qualities, making it often unattainable to material scientists and engineers. QOVID offers a solution to fill this gap
between MEMS and biomedicine by developing a commercialization solution for piezoelectric a-quartz resonating devices to detect
the mass response of SARS-CoV-2 spike molecular interactions as an original readout of viral loads. QOVID builds on the technology
developed during the ERC Starting Grant SENSiSOFT to provide a user-friendly versatile Bio-MEMS sensor prototype that will give
researchers in the life sciences and biomedical sector without an engineering or electronic training a reliable diagnostic tool to detect
SARS-CoV-2 and other respiratory viruses.
QOVID will scale up a new generation of On-chip epitaxial piezoelectric a-quartz/Si MEMS manufactured exclusively by soft-chemistry
with CMOS-compatible processes offering cost-efficient single-chip solutions not only for biomedical applications but also for many
other fields. These a-quartz bioMEMS will have thicknesses between 200 nm and 1 µm, this is between 10 to 50 times thinner and 10
to 100 times more sensitive than those obtained by traditional top-down technologies on bulk crystals.
QOVID will pursue commercialization and market solutions both within academia and the biotechnology and biomedical among other sectors. |
